商品描述
Tuberculosis (TB) is the leading cause of death by an infectious agent worldwide. The Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against TB and the most widely used vaccine in history. Since 1921, billions of people have been vaccinated with BCG, resulting in a remarkable decline in infant mortality. However, although BCG's efficacy to prevent TB meningitis and disseminated disease in children is well established, its efficacy to prevent infection, disease or reactivation in adolescents and adults is variable. Therefore, novel TB vaccines are urgently needed. Recent clinical trials have shown promising results, offering hope for the introduction of a new generation of vaccines to replace or boost BCG. The book is structured into five sections, each providing sequential relevance to understanding the current landscape and future developments in TB vaccines. Section 1 introduces TB and the causative agent, Mycobacterium tuberculosis. Section 2 presents historical perspectives on BCG and TB vaccine candidates. Section 3 focuses on pre-clinical vaccines against TB. Section 4 examines vaccines against TB currently in clinical trials. Finally, section 5 discusses public health and societal challenges associated with the development of TB vaccines. This book is an essential tool for students, clinicians, and scientists working in the fields of mycobacteriology, vaccine immunology, vaccine development, and TB vaccines, and it is anticipated to stimulate future research in TB vaccine development.
商品描述(中文翻譯)
結核病（TB）是全球由傳染病原引起的主要死亡原因。卡介苗（BCG）是唯一獲得許可的結核病疫苗，也是歷史上使用最廣泛的疫苗。自1921年以來，已有數十億人接種了BCG，這導致嬰兒死亡率顯著下降。然而，儘管BCG在預防兒童結核性腦膜炎和播散性疾病方面的有效性已得到充分證實，但其在預防青少年和成人的感染、疾病或再活化方面的有效性則變化不定。因此，迫切需要新型結核病疫苗。最近的臨床試驗顯示出令人鼓舞的結果，為引入新一代疫苗以取代或增強BCG帶來了希望。
本書分為五個部分，每個部分都與理解結核病疫苗的當前狀況和未來發展具有連貫的相關性。第一部分介紹結核病及其病原體，結核分枝桿菌（Mycobacterium tuberculosis）。第二部分提供有關BCG和結核病疫苗候選者的歷史觀點。第三部分專注於針對結核病的臨床前疫苗。第四部分檢視目前正在臨床試驗中的結核病疫苗。最後，第五部分討論與結核病疫苗開發相關的公共衛生和社會挑戰。
本書是從事分枝桿菌學、疫苗免疫學、疫苗開發和結核病疫苗領域的學生、臨床醫生和科學家的重要工具，預期將促進未來在結核病疫苗開發方面的研究。
作者簡介
Paulo J. G. Bettencourt holds a BSc in Biotechnology from ISHT in Lisbon, Portugal, a Master's degree in Immunology and Immunogenetics from the University of Manchester, UK, and a PhD in Pharmacy from the University of Lisbon, Portugal. He completed seven years of post-doctoral research in Vaccinology at the renowned Jenner Institute at Oxford University, UK, where the ChAdOx1-S/nCoV-19 vaccine against COVID-19, and the R21 vaccine against malaria were developed. Currently, he is an Assistant Professor, Principal Investigator, Director of the Research and Teaching Laboratories, and Coordinator of the MSc in Immunology and Vaccinology, at the new Faculty of Medicine at the Universidade Católica Portuguesa (UCP), which he co-founded. Additionally, he was appointed as the coordinator of the platform CatólicaMed at the Center for Interdisciplinary Research in Health, at UCP. His postdoctoral research has led to the identification of three new candidate antigens for TB vaccines, currently in preclinical development. Prof. Bettencourt's current research is focused on three main areas: 1) the interaction between pathogens and the immune system focusing on the discovery of antigens using immunopeptidomics, 2) the translation of fundamental immunology into the design of mRNA vaccines against TB, malaria, and Staphylococcus aureus infections, and 3) the impact of Vaccination in Global Health. Through the combination of immunology and vaccinology, Prof. Bettencourt aims to contribute to the development of innovative medical interventions with significant importance and impact for humanity.
作者簡介(中文翻譯)
保羅·J·G·貝滕科特擁有葡萄牙里斯本ISHT的生物技術學士學位、英國曼徹斯特大學的免疫學與免疫遺傳學碩士學位，以及葡萄牙里斯本大學的藥學博士學位。他在英國牛津大學著名的詹納研究所完成了七年的疫苗學博士後研究，該所開發了針對COVID-19的ChAdOx1-S/nCoV-19疫苗和針對瘧疾的R21疫苗。
目前，他是葡萄牙天主教大學（UCP）新醫學院的助理教授、首席研究員、研究與教學實驗室主任，以及免疫學與疫苗學碩士課程的協調員，並且是該學院的共同創辦人。此外，他還被任命為UCP健康跨學科研究中心的CathólicaMed平台協調員。
他的博士後研究導致了三種新的結核病疫苗候選抗原的識別，目前正處於臨床前開發階段。貝滕科特教授目前的研究集中在三個主要領域：1）病原體與免疫系統之間的相互作用，專注於利用免疫肽組學發現抗原；2）將基礎免疫學轉化為針對結核病、瘧疾和金黃色葡萄球菌感染的mRNA疫苗設計；3）疫苗接種對全球健康的影響。
通過免疫學和疫苗學的結合，貝滕科特教授旨在為人類開發具有重要性和影響力的創新醫療干預措施做出貢獻。
